Capricor Therapeutics EBIT

As of the most recent data (June 2026), CAPR shows a EBIT of $-43B. That compares with $-13B in the prior-year period — down 229.3% year over year. That is below the Healthcare sector average of $23B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CAPR's EBIT is now $-43B (was $-13B) — a 229.3% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Capricor Therapeutics is outperforming or lagging.

The Healthcare sector average EBIT is about $23B. Capricor Therapeutics is at $-43B, which is lower that average. That is roughly 287.3% below the sector mean. Use the comparison chart on this page to see how CAPR stacks up against individual peers as well.

Tracking CAPR's ebit over time shows whether Capricor Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $-43B That compares with $-13B in the prior-year period — down 229.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Capricor Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-43B) with ownership activity and broader fundamentals.